Research programme: RNA interference-based respiratory disorder therapeutics - Alnylam

Drug Profile

Research programme: RNA interference-based respiratory disorder therapeutics - Alnylam

Alternative Names: siRNA targeting IKK-beta - Alnylam; siRNA targeting IKK2 - Alnylam

Latest Information Update: 14 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Imperial College of Science, Technology and Medicine; Justus Liebig University
  • Class Small interfering RNA
  • Mechanism of Action I-kappa B kinase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pulmonary fibrosis; Respiratory tract disorders

Most Recent Events

  • 18 Oct 2013 Discontinued - Preclinical for Pulmonary fibrosis in Germany (Parenteral)
  • 18 Oct 2013 Discontinued - Preclinical for Respiratory tract disorders in Germany (Parenteral)
  • 06 May 2011 No development reported - Preclinical for Pulmonary fibrosis in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top